Clinical trials: Molecular Targeted Therapy
Breast Cancer
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Trial name
- NCT02597179
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Advanced Non-small Cell Lung Cancer (NSCLC)
Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway
This multicenter pilot observational study aims to assess the feasibility of introducing liquid biopsy at an early stage of the diagnostic pathway for patients with suspected advanced non-small cell lung cancer (NSCLC).
- Trial name
- INNOVA-LUNG (NCT07649629)
- Testing
- Plasma-based liquid biopsy
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Regina Elena Cancer Institute
Lung Neoplasms, Psychological Distress
Association of Psychological Distress in Patients With Lung Cancer
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment.
- Conditions
- Lung Neoplasms, Psychological Distress, Prognosis Factors, Lifestyle, Healthy
- Trial name
- Life-Score (NCT06218901)
- Testing
- immunotherapy, Targeted Therapy Agent
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Metastatic Melanoma
Multicenter Tissue Registry in Melanoma
The prospective multicenter translational study Tissue Registry in Melanoma (ADOREG/TRIM; CA209-578) aimed to validate the Tumor Mutational Burden (TMB) and the PD-L1 expression (PD-L1) from a pre-therapeutically obtained tumor…
- Trial name
- TRIM (NCT05750511)
- Testing
- molecular tissue analysis
- Where
- 14 sites in Germany
- Volunteers
- 1,000 people
- Sponsor
- Dermatologic Cooperative Oncology Group
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Non Small Cell Lung Cancer
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
A prospective ,multicenter ,non-interventional ,real-world study observing changes in molecular markers after three weeks of osimertinib targeted therapy in EGFRm NSCLC
- Trial name
- pre-FLAME (NCT06422546)
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Beijing Cancer Prevention & Treatment Society
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Rare Diseases, Aniridia
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
The cross-sectional observational clinical study related to rare eye diseases is a multi-center study in which the hypothesis is that neurokinin 1 receptor and/or substance P expression is increased in REDs associated with…
- Conditions
- Rare Diseases, Aniridia, Neurotrophic Keratopathy, Limbal Stem Cell Deficiency
- Trial name
- NCT06412718
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- IRCCS Ospedale San Raffaele
Hepatocellular Carcinoma
Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with…
- Trial name
- NCT06607120
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Zhongda Hospital
Lung Neoplasms
Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.
This is a non-interventional multi-center with investigational sites in Chile and Brasil diagnostic study to validate novel diagnostic technologies, such as Next Generation Sequencing (NGS) from both tissue and blood compared to…
- Trial name
- NIRVANA (NCT03220230)
- Where
- 37 sites in Brazil, Chile and 1 more
- Volunteers
- 4,240 people
- Sponsor
- Pfizer
Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging
CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma
⁶⁸Ga-NOTA-BCMA is a novel, targeted PET tracer under clinical investigation. It is designed to provide a non-invasive method for monitoring the biodistribution and persistence of BCMA CAR-T cells in patients.
- Conditions
- Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence, GMP-compliant Radiopharmaceutical Preparation
- Trial name
- NCT07280793
- Testing
- BCMA-Targeting CAR-T Cell Therapy, PET/CT Imaging
- Volunteers
- 10 people
- Sponsor
- Xuzhou Medical University
Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of dalteparin when given together with sunitinib malate in treating patients with kidney cancer that has spread to other parts of the body or cannot be removed by surgery.
- Conditions
- Clear Cell Sarcoma of the Kidney, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT01061411
- Testing
- Dalteparin, Pharmacological Study, Sunitinib Malate
- Where
- 4 sites in United States, Netherlands
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Gastric Cancer, HER2 + Gastric Cancer
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling…
- Conditions
- Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
- Trial name
- NCT06881017
- Testing
- Trastuzumab, Adebrelimab, Apatinib
- Volunteers
- 140 people
- Sponsor
- China Medical University, China
Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure
This is a prospective phase II clinical trial to evaluate the efficacy and safety of apatinib and camrelizumab in recurrent or metastatic nasopharyngeal carcinoma who failed at least the first-line treatment.
- Conditions
- Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect
- Trial name
- NCT04586088
- Testing
- Apatinib plus Camrelizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Castration-resistant Prostate Cancer, Prostate Cancer Metastatic
Selective Treatment According to Molecular Subtype of Prostate Cancer
This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers.
- Trial name
- STAMP (NCT03696186)
- Testing
- Luminal type-1, Luminal type-2, Neuroendocrine type-1
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tianjin Medical University Second Hospital
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT04521153
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy
This is a prospective trial for a computation-based efficacy prediction method for anticancer target therapies. The original computational algorithm utilizes individual transcriptome data of a cancer sample and assesses changes…
- Trial name
- NCT03724097
- Testing
- RNA sequencing, Transcriptome analysis, target drug with the score above 0,1
- Where
- 7 sites in United States, Russia
- Volunteers
- 200 people
- Sponsor
- OmicsWay Corp.
Metastatic Breast Cancer
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial).
- Trial name
- HOPE-Focus (NCT06991946)
- Testing
- Liquid Biopsy, Archival Tumor DNA
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- SOLTI Breast Cancer Research Group